Cloud 9fin

Distressed Diaries — Cerba creditors' patience gets tested

Jun 19, 2025
Denitsa Stoyanova, a senior distressed credit analyst at 9fin, shares insights into Cerba, a French lab company facing severe financial turmoil. Cerba's debt has soared amidst government tariff cuts, with creditors now organizing for potential negotiations. The unexpected resignation of CEO Emmanuel Ligner adds to the drama, while net leverage ratios climb. Denitsa discusses critical cost-saving strategies, the impact of asset sales, and the urgency for Cerba to reduce its staggering debt from $4.8 billion to $2.7 billion for long-term viability.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Tariff Cuts Pressure Revenues

  • Cerba's lab testing prices are regulated and set by the French government with no influence from Cerba.
  • Recent tariff cuts have pressured revenues, but Cerba has offset about 80% of cuts through volume gains.
INSIGHT

Cost Savings Target Challenges

  • Cerba aims to save 106 million euros in costs over two years, mostly through staff cuts and platform consolidation.
  • Only 11 million was saved in Q1 2025, indicating they are behind schedule but plan to ramp up efforts.
INSIGHT

Muted Asset Sale Strategy

  • Cerba's recent divestments are limited; it sold its veterinary business for 70 million euros.
  • The Italian Testing, Inspection, and Certification business may be next to sell, potentially fetching 115 million euros.
Get the Snipd Podcast app to discover more snips from this episode
Get the app